Cessatech A/S approved for listing at Spotlight Stock Market
Cessatech is a Danish clinical Phase II company developing evidence-based treatment for children. Its lead asset (CT001) is an analgesic nasal spray for treatment of acute and planned painful procedures in children. Cessatech recently reached an essential target with the approval by the EMA to launch its Paediatric Investigation Plan (PIP), which grants the Company an approved path for a Paediatric-use Marketing Authorization (PUMA) and thereby the opportunity to launch CT001 in Europe in just a few years.Cessatech is committed to developing and commercialising evidence-based and innovative